Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Solid Biosciences Inc., a life sciences company that acquired UF startup AavantiBio, announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s, AAV-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA).
Solid Biosciences Announces FDA IND Clearance for First-in-Industry Dual Route of Administration Gene Therapy To Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Solid Biosciences Inc., a biotechnology company that acquired UF startup AavantiBio, announced that the U.S. FDA has cleared its Investigational New Drug application for SGT-212 for the treatment of Friedreich’s ataxia.
24-Year-Old Researches Treatment for Her Own Crippling Disease: ‘I’m in a Race Against Time’
Shandra Trantham has Friedreich’s ataxia (FA), a rare genetic disease that is slowly robbing her of the ability to walk and talk, and can also affect her heart. FA is caused by an inability in the body to make frataxin, a protein that is necessary for normal cell function. To date, there is no cure and no approved treatments — but she’s working on one. She’s a 4th-year Ph.D. candidate in genetics and genomics at the University of Florida Powell Gene Therapy Center. Trantham works in a lab where gene therapy for FA is being fine-tuned.
AavantiBio and Resilience Announce Strategic Collaboration for Gene Therapy Development and Manufacturing
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and National Resilience, Inc. (Resilience), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem and who recently acquired UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices, announced a strategic collaboration to support the development and manufacturing of AavantiBio’s pipeline of therapies, including its lead program in Friedreich’s Ataxia (FA).